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The endogenous healing potential of avascular meniscal lesions is poor. Up to now, partial meniscectomy is still the treatment of
choice for meniscal lesions within the avascular area. However, the large loss of meniscus substance predisposes the knee for
osteoarthritic changes. Tissue engineering techniques for the replacement of such lesions could be a promising alternative
treatment option. Thus, a polyurethane scaﬀold, which is already in clinical use, loaded with mesenchymal stromal cells, was
analyzed for the repair of critical meniscus defects in the avascular zone. Large, approximately 7mm broad meniscus lesions
aﬀecting both the avascular and vascular area of the lateral rabbit meniscus were treated with polyurethane scaﬀolds either
loaded or unloaded with mesenchymal stromal cells. Menisci were harvested at 6 and 12 weeks after initial surgery. Both cell-
free and cell-loaded approaches led to well-integrated and stable meniscus-like repair tissue. However, an accelerated healing
was achieved by the application of mesenchymal stromal cells. Dense vascularization was detected throughout the repair tissue
of both treatment groups. Overall, the polyurethane scaﬀold seems to promote the vessel ingrowth. The application of
mesenchymal stromal cells has the potential to speed up the healing process.
1. Introduction
Lesions of the meniscus are amongst the most frequent knee
injuries in orthopedic surgery [1, 2]. In many cases, partial
meniscectomy has to be performed due to the poor endoge-
nous healing capacity of avascular parts of the meniscus
[2–4]. However, the loss of meniscus continuity predisposes
for the development of osteoarthritic changes, which corre-
lates with the amount of resected meniscus substance [5–7].
The meniscus has a decisive functional and biomechani-
cal relevance for an intact knee joint [8, 9]. The knee menisci
provide essential qualities in load bearing and shock
absorption as well as in stabilization, lubrication, and propri-
oception of the knee joint [10–14]. (Partial) Meniscectomy
causes severe changes in the biomechanics of the knee joints.
The eﬀect is directly proportional to the amount of lost tissue
[15] and results in drastically increased contact pressure [16].
Therefore, it is of importance to restore as much meniscus
tissue as possible.
Successful repair strategies for lesions in the vascular
zone of the meniscus like suturing have already been devel-
oped [17, 18]. However, up to now, there is still no estab-
lished curative therapy for lesions within the avascular parts
of the meniscus in clinical practice [19–21].
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According to the current literature, mesenchymal stro-
mal cells (MSC) are the focus of attention in newly developed
approaches for meniscus repair [2, 21–27]. As these cells
have both the potential to diﬀerentiate into ﬁbrochondro-
cytes and the ability to secrete repair-promoting growth
factors, they seem to be an ideal tool for meniscus repair
[22, 28, 29]. Preclinical studies have already shown the repair
potential of mesenchymal stromal cells in combination with
a scaﬀold in the treatment of small tears, punch defects in
the avascular zone of the meniscus, and full-size meniscal
defects [2, 12, 23, 24, 27].
There are also a few clinical studies showing promising
results after application of MSCs for meniscus regeneration
in humans [21, 30].
However, clinical translation of these repair approaches
has not been achieved. The polyurethane scaﬀold (Actiﬁt®,
Orteq, London, UK) used in this study has successfully
been clinically applied in a cell-free approach in recent
years [1, 31–39]. Therefore, the aim of this study was to
investigate the eﬀect of a polyurethane scaﬀold (Actiﬁt,
Orteq, London, UK) loaded with mesenchymal stromal
cells concerning the eﬀectiveness of a combination of mes-
enchymal stromal cells and this scaﬀold for the treatment
of large, critical size combined vascular and avascular
meniscus defects. Special emphasis was given on vascular-
ity as an important factor for the integration of the repair
tissue in the native surrounding meniscus.
2. Material and Methods
The local government’s animal rights protection authorities
approved this study in accordancewith theNational Institutes
of Health guidelines for the use of laboratory animals.
2.1. Study Design. 14male New Zealand white rabbits aged 12
to 14 weeks and weighing 2.8 to 3.2 kg were used. Each animal
received the study treatment on the right knee joint and the
control treatment on the left knee joint. Depending on the
study period of 6 or 12 weeks, two groups were diﬀered from
each group consisting of 7 animals. No randomization or
matchingwas done to allocate the animals to the experimental
groups. All animals were kept in single animal cages with free
access to food and water.
2.2. Bone Marrow-Derived Mesenchymal Stromal Cells:
Harvest and Culture. For the preparation of the study treat-
ment, bone marrow-derived MSCs were harvested 4 weeks
before the index surgery. The bone marrow harvest and
MSC cell isolation was performed as previously described
[22, 40]. The New Zealand white rabbits were anesthetized
using a combined intramusculary application of 0.6ml/kg
of ketamine 10% and xylazin 2%. Bone marrow-derived mes-
enchymal stromal cells were harvested by puncturing the
iliac crest of the rabbits on both sides by a small incision
and penetrating the bone cortex with an 18-gauge needle.
The bone marrow was collected into a heparinized syringe.
Dulbecco’s modiﬁed Eagle’s medium (DMEM), low glucose
concentration, with 10% fetal bovine serum, 1% penicillin,
and 1% HEPES, was added to the aspirate. Nucleated cells
(20× 106) were plated in 75 cm2 culture dishes and cultivated
at 37°C. Plastic adhesion distinguishes MSCs from other cell
populations as previously described [41–43]. The medium,
containing DMEM, low glucose concentration, 10% fetal
bovine serum, 1% penicillin, 1% HEPES, and 0.01% ﬁbro-
blast growths factor, was changed after one week of adhesion
twice a week until the adherent cells (MSCs) reached 80%
conﬂuence [3].
2.3. Polyurethane Scaﬀolds. Commercially available polyure-
thane scaﬀolds Actiﬁt (Orteq, London, UK) were used for this
study. The material was cut in small parts approximately ﬁt-
ting the planned meniscus defects. Before use, these scaﬀolds
were sterilized with 25 kGy beta rays (Beta-Gamma-Service
GmbH, Saal, Germany).
2.4. Loading of the Polyurethane Scaﬀolds. Depending on the
group, the ﬁtted polyurethane scaﬀolds were loaded with
either 200μl of the MSC cell suspension or 200μl of cell-
free chondrogenic medium.
The cell suspension contained 2× 104 nucleated cells/μl
resuspended in chondrogenic medium. The chondrogenic
medium consisted of the same ingredients like the cell-free
chondrogenic medium except for the additional nucleated
cells. The cell-free chondrogenic medium contained DMEM,
high glucose concentration (4500mg/l), with 10% pyruvate,
10% ITS, 10% dexamethasone, 10% TGFβ1, and 10% ascor-
bic acid as previously described [25].
The loading process of the scaﬀolds was achieved using a
rotary valve vacuum pump (Vacuubrand GmbH, Wertheim,
Germany) as already described by Achatz et al. [44].
Subsequently, the loaded scaﬀolds were incubated at 37°C
for 1 hour and then kept in chondrogenic media overnight to
allow cell adherence before being implanted the following
day. Pretests showed a successful loading of the scaﬀolds.
2.5. Surgical Procedure for Meniscus Defects. In vivo experi-
ments were performed bilaterally in 14 New Zealand white
rabbits. One blinded experienced orthopedic surgeon
performed all surgical procedures.
The New Zealand white rabbits were anesthetized using a
combined intramuscular application of 0.6ml/kg of ketamine
10% and xylazin 2%. For the dissection of the lateral menisci,
the lateral knee joint compartment was opened by lateral
parapatellar arthrotomy. The lateral meniscus was luxated
anteriorly by a limited soft tissue release. In the pars interme-
dia, a partial meniscectomy sized 7× 3 mm was performed.
The created combined vascular and avascular defect pre-
sented a complete discontinuance of the meniscus circumfer-
ence. The meniscus defects were ﬁlled with Actiﬁt scaﬀolds,
on the one site loaded with mesenchymal stromal cells and
on the contralateral site with a cell-free polyurethane scaf-
fold. Preparation of the scaﬀolds was performed as described
above. Subsequently, the scaﬀolds were attached site to site to
the crus anterior and posterior of the lateral meniscus with a
resorbable 4-0 suture.
Wound healing was checked daily. Postoperative pain
control was achieved by subcutaneous application of carpro-
fen 5mg/kg. There were no limitations concerning move-
ment and weight bearing postoperative. The animals were
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euthanized at 6 or 12 weeks by an intravenous application of
an overdose of narcoren (0.5 g/kg). The New Zealand white
rabbits were anesthetized using a combined intramuscular
application of 0.6ml/kg of ketamine 10% and xylazin 2%
beforehand.
2.6. Gross Assessment of Joint Morphology. The gross assess-
ment of joint morphology was conducted as described previ-
ously by Zellner et al. [24]. Rabbits were euthanized in deep
narcosis with an overdose of narcoren intravenously depend-
ing on the group 6 or 12 weeks after the implantation of the
scaﬀolds. Knee joints were exposed, and the menisci were
harvested. Afterwards, the macroscopic morphology of the
meniscus and the joint compartment were evaluated and
photographed. The correct anatomic location of the menisci,
the macroscopic integration of the repair tissue, the state of
the meniscus surface, and the color changes were evaluated.
Eventual signs of degenerative changes in terms of osteo-
phyte development and cartilage deterioration were docu-
mented. All menisci and knee joints were analyzed by two
experienced and blinded scorers, and the results were
collected for an established scoring system. Afterwards, the
lateral menisci were harvested for further histological exam-
ination and photographic documentation.
2.7. Histology. The lateral menisci were ﬁxed in a solution
containing 4% paraformaldehyde and 15% picric acid,
embedded in Tissue-Tek OCT (Sakura Finetek, Tokyo,
Japan) and frozen in liquid nitrogen. All samples were cut
in 10μm transversal sections, and every 10th of them was
stained with dimethylmethylen blue (DMMB). The content
of proteoglycan was determined according to the percentage
of the ﬁlling of the porous area of the scaﬀolds by stained
extracellular matrix.
Overall, two blinded scorers, both experienced in the knee
anatomy of rabbits and in histological assessment, analyzed
the sections according to the established scoring system. [13]
2.8. Immunohistochemistry
2.8.1. Type II Collagen. The frozen sections, embedded in
Tissue-Tek OCT (Sakura Finetek, Tokyo, Japan), were
washed in a phosphate-buﬀered saline and digested with
0.1% pepsin at pH 3.5 for 15 minutes to facilitate antibody
access to the target epitopes. Type II collagen was immuno-
localized by the immunoperoxidase ABC technique (Vector,
Burlingame, CA, USA). As primary antibodies, anticollagen
II (clone II-4C11; Calbiochem Merck, Schwalbach
Germany) was used. The antibody dilution was 1 : 100. After
staining with biotin conjugated polyclonal goat anti-mouse
IgG secondary antibody (Jackson, West Grove, PA, USA),
positive signals were visualized by nickel and cobalt-
enhanced 3,3′-diaminobenzidine (DAB) [13, 23].
Concerning the evaluation of the content of collagen type
II, the percentage of collagen type II stained area within the
extracellular matrix in the porous area of the scaﬀolds was
assessed in comparison to the extracellular matrix in the
DMMB-stained samples.
2.8.2. CD 31. For the evaluation of vascularization, CD 31
immunohistochemistry was performed almost consistent to
type II collagen immunohistochemistry (described above).
The procedure diﬀered in two facts. No pepsin digestion
was performed, and primary monoclonal CD31 mouse anti-
rabbit antibodies (clone JC-70A IgG1 light chain-type kappa;
Abcam, Cambridge, UK) were used with a dilution of 1 : 50.
2.9. Meniscus Scoring System. For standardized evaluation
and comparison of the meniscus repair, an established scor-
ing system was applied. It has previously been published by
Zellner et al. [23, 24] for the evaluation of the repair of menis-
cal punch defects and meniscal tears.
Scoring items of the macroscopical analysis were stability
and defect ﬁlling with repair tissue. The quality of the surface
area, the integration of the repair tissue in the nativemeniscus,
cellularity, cell morphology and the content of proteoglycan
were subgroups of the histological assessment. The expression
of collagen II was analyzed by immunohistochemistry.
That way, 8 individual scoring subgroups were formed,
each receiving a scoring value ranging from 0 (no repair) to
3 (meniscus-like tissue). The values of these items were
summed up, consequently reaching a combined score from
0 (no repair) to 24 (complete reconstitution of the meniscus)
(Table 1). Two experienced blinded scorers conducted the
data collection. A high internal consistency has been attrib-
uted to this scoring system (Cronbach’s alpha= 0.88) [24].
By this, validated scoring system results can be easily inter-
preted and compared to other results.
2.10. Statistical Analysis. Statistical analysis was performed
using the SPSS software version 23.0 (SPSS, Chicago, IL,
USA) to determine relationships between variables. To deter-
mine whether data followed a Gaussian distribution, a
Kolmogorov-Smirnov test was conducted. For comparison
of normal distributed data, a paired t-test was used. For non-
normal distributed data, the Mann–WhitneyU test was used.
A probability value of less than 0.05 was set as the level of sta-
tistical signiﬁcance for all evaluations.
3. Results
3.1. Cell-Free Polyurethane Scaﬀold: 6 Weeks. The evaluation
of the menisci of the New Zealand white rabbits after menis-
cus defect therapy with cell-free polyurethane scaﬀolds and a
study period of 6 weeks n = 7 showed macroscopically dis-
tinguishable meniscus defects. In one animal, almost a com-
plete ﬁlling of the meniscal defect was observed. The
remaining menisci showed a partial ﬁlling of the meniscus
defects. Regarding the meniscus surface, in four cases, the
meniscus surface was ﬁssured, whereas in three menisci,
complete ruptures were present. Overall, one meniscus
showed a complete integration of the polyurethane scaﬀold
to the surrounding meniscus tissue. In three cases, bilateral
partial or unilateral complete integration was observed. In
the remaining three menisci, only unilateral partial integra-
tion was found. When evaluating the cellularity of the menis-
cus scaﬀold in comparison to the native meniscus tissue, in
all cases, the cell number within the meniscal repair tissue
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was higher than that within the native meniscus tissue, with
less than a quarter of cells registered as meniscus-like cells
found. The repair tissue generally showed a lower content
of proteoglycans and type II collagen in comparison to the
surrounding meniscus tissue. The stability testing showed
only a low stability and the developed tissue appeared soft
and ruptured. Signs of inﬂammation or foreign body reaction
were found in none of the animals (see Figure 1).
3.2. Mesenchymal Stromal Cell-Loaded Polyurethane Scaﬀold:
6 Weeks. In the group of meniscal defects treated with a mes-
enchymal stromal cell-loaded polyurethane scaﬀold n = 7
in four animals. an almost complete defect ﬁlling was seen.
In the remaining three cases, over half of the defect was ﬁlled.
In all menisci, the surface of the repair tissue was ﬁssured
without any complete ruptures. Regarding the integration,
in three menisci, a bilateral complete integration of the cell-
loaded scaﬀolds to the surrounding native meniscus tissue
was observed. In four cases, only unilateral complete or bilat-
eral partial integration was reached. The cellularity of the
developed tissue was more than a quarter higher than the
native surrounding meniscus tissue. Whereas the type II col-
lagen content appeared generally low, the content of proteo-
glycans ranged between 25% and 75% in comparison to the
native meniscus tissue. The new developed tissue of six ani-
mals was stable in shape. In one animal, the repair tissue
was of poor quality and ruptured during stability testing.
Signs of inﬂammation or foreign body reaction were found
in none of the animals (see Figure 2).
3.3. Cell-Free Polyurethane Scaﬀold: 12 Weeks. Regarding
cell-free polyurethane scaﬀolds after a study period of 12
weeks n = 7 , two menisci showed a complete defect ﬁlling.
A partial defect ﬁlling was observed in 4 menisci, and in
one case, just a marginal ﬁlling was seen. In three cases, the
surface of the repair tissue appeared to be meniscus-like. In
three cases, it seemed to be ﬁssured, and in one case, it
completely ruptured. In two menisci, the full integration of
polyurethane scaﬀolds into the native meniscus was
achieved. In ﬁve cases, the repair tissue integrated partially
bilateral or completely unilateral. The cellularity of the new
formed tissue was higher than that in the surrounding native
meniscus tissue. In ﬁve cases, approximately half of the cells
were of meniscus-like morphology, whereas in two cases, less
than a quarter of the cells showed meniscus-like morphology.
The proteoglycan content was below 25% in two menisci
and ranged between 25% and 75% in ﬁve cases. The content
of type II collagen was less than 25% in six menisci and
ranged between 25% and 75% in one case. In the stability
testing, six menisci were in shape, and in one case, it
appeared soft and ruptured. None of the animals showed
signs of inﬂammation or foreign body reaction (see Figure 3).
3.4. Mesenchymal Stromal Cell-Loaded Polyurethane Scaﬀold:
12 Weeks. 12 weeks after meniscus defect treatment with
mesenchymal stromal cell-loaded polyurethane scaﬀolds
n = 7 , an almost complete defect ﬁlling was achieved in
two cases, while in ﬁve cases, the defect ﬁlling was more than
half. Complete ruptures did not occur. In three menisci, the
surface of the repair tissue appeared to be meniscus-like,
whereas in four cases, the surface seemed to be ﬁssured. A
complete integration into the surrounding native meniscus
was reached in two cases. A unilateral complete or bilateral
partial integration was observed in four menisci. Only one
animal presented with partial unilateral integration. The cel-
lularity of the new formed tissue was higher than that in
native meniscus tissue, and in almost all cases, between
25% and 75% of the cells showed meniscus-like morphology.
While in almost all animals, the content of proteoglycan
ranged between 25% and 75% and only two animals reached
a content of type II collagen higher than 25%. The repair tis-
sue was stable and in shape in ﬁve cases and appeared
weak and ruptured in another two cases. None of the
animals showed signs of inﬂammation or foreign body
reaction (see Figure 4).
3.5. Meniscus Scoring. After six weeks, the meniscus scoring
showed overall signiﬁcant higher values p < 0 05 in the
Table 1: Meniscus scoring system for the evaluation of meniscus repair tissue [23, 24].
0 1 2 3
Defect-ﬁlling No ﬁll <25% 25–75% >75%
Surface No surface Ruptured Fissured/ﬁbrillated Meniscus-like
Integration No integration
Partial, unilateral
integration
Bilateral partial or
unilateral
complete integration
Bilateral complete
integration
Cellularity No cells >10 cell cluster/slide No cell cluster/slide,cell-ECM ratio > 0 5
Meniscus-like cell-ECM
ratio
Cell morphology No cells <25% meniscus-like cells 25–75% meniscus-like
cells
>75% meniscus-like cells
Content of
proteoglycan
No staining for
proteoglycan
<25% 25–75% >75%
Content of collagen II No staining for collagen II <25% 25–75% >75%
Stability No stability Weak Stable in shape
Stable to pressure and
pulling stress
ECM= extracellular matrix.
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group of mesenchymal stromal cell-loaded polyurethane
scaﬀolds (mean: 15.6, SD: ±1.3) in comparison to the
group of cell-free polyurethane scaﬀolds (mean: 10.4, SD:
±0.7) (Figure 5).
Moreover, the histological evaluation showed a signiﬁ-
cantly higher content of proteoglycans in the group of
mesenchymal stromal cell-loaded polyurethane scaﬀolds
(mean: 2.0, SD: ±0.1) as observed in the group of cell-
free polyurethane scaﬀolds (mean: 1.1, SD: ±0.4) after 6
weeks. The signiﬁcant advantage of the mesenchymal stro-
mal cell loading is lost after 12 weeks (Figure 6).
Regarding the integration of the polyurethane scaﬀolds
into the surrounding meniscus tissue, a signiﬁcantly better
integration could be obtained by mesenchymal stromal cell
a
b
c
b
b
a
Figure 1: Left: macroscopic view on a lateral meniscus (b). The defect is ﬁlled with a cell-free polyurethane scaﬀold (a) 6 weeks after
implantation. Right: microscopic view; DMMB staining of the cell-free polyurethane scaﬀold (a) and surrounding meniscus tissue
(b = avascular part; c = vascular zone) 6 weeks after implantation. Unilateral integration on the left side and no integration on the right
side. Benchmark for both ﬁgures: bar = 2mm.
a b
c a
b
Figure 2: Left: macroscopic view on a lateral meniscus (b = avascular part; c = vascular part). The defect is ﬁlled with a mesenchymal
stromal cell-loaded polyurethane scaﬀold (a) completely surrounded by native meniscus tissue 6 weeks after implantation. Right:
microscopic view; DMMB staining of the mesenchymal stromal cell-loaded polyurethane scaﬀold (a) and surrounding meniscus
tissue (b = avascular part; c = vascular zone) 6 weeks after implantation. Bilateral integration into the surrounding meniscus tissue.
Benchmark for both ﬁgures: bar = 2mm.
c
b
a a
b
c
Figure 3: Left: macroscopic view on a lateral meniscus (b = avascular part; c = vascular part). The defect is ﬁlled with a cell-free polyurethane
scaﬀold (a) completely surrounded by native meniscus tissue 12 weeks after implantation. Right: microscopic view; DMMB staining of the
cell-free polyurethane scaﬀold (a) and surrounding meniscus tissue (b = avascular part; c = vascular zone) 12 weeks after implantation.
Bilateral integration into the surrounding meniscus tissue. Benchmark for both ﬁgures: bar = 2mm.
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loading (MSC-loaded polyurethane scaﬀolds 2.4 SD± 0.5 ver-
sus cell-free polyurethane scaﬀolds 1.6 SD± 0.6; p < 0 05)
(Figure 7).
Overall, after 12 weeks, no signiﬁcantly better menis-
cus scoring results were obtained for the treatment of
combined vascular and avascular meniscus defects by mes-
enchymal stromal cell loading of polyurethane scaﬀolds in
comparison to cell-free polyurethane scaﬀolds (mean over-
all score 15.3SD± 14 versus 14.5 SD± 1.7; p > 0 05)
(Figure 5). Additionally, no signiﬁcant diﬀerences were
detected in the meniscus scoring subcategories.
3.6. Meniscus Vascularization. In addition to the regenerative
potential, vascularization of the repair tissue of all harvested
menisci (n = 28 menisci of 14 animals) was assessed by
CD31 immunohistochemistry. Consistent results were
obtained for all groups. No diﬀerences between mesenchymal
stromal cell-loaded polyurethane scaﬀolds n = 14 and cell-
free n = 14 polyurethane scaﬀolds were observed. Also, the
study period of 6 or 12 weeks showed no inﬂuence on the
results. Overall dense vascularization was observed in each
histological cut showing an abundance of various-sized trans-
verse and longitudinal vessel cuts (Figure 8). Vessels were
detected both in the part of the repair tissue corresponding
to the peripheral, vascular area of the native meniscus, and in
the repair tissue corresponding to the avascular zone of the
native meniscus.
b a
cc
b
a
Figure 4: Left: macroscopic view on a lateral meniscus (b = avascular part; c = vascular part). The defect is ﬁlled with a mesenchymal
stromal cell-loaded polyurethane scaﬀold (a) completely surrounded by native meniscus tissue 12 weeks after implantation. Right:
microscopic view; DMMB staining of the mesenchymal stromal cell-loaded polyurethane scaﬀold (a) and surrounding meniscus
tissue (b = avascular part; c = vascular zone) 12 weeks after implantation. Bilateral integration into the surrounding meniscus tissue.
Benchmark for both ﬁgures: bar = 2mm.
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Figure 5: Mean meniscus scoring value: comparison of all meniscus
score results of cell-free polyurethane scaﬀolds (= cell free) and
mesenchymal stromal cell-loaded scaﬀolds (= MSC) after 6 and 12
weeks. (∗ ) describes signiﬁcant diﬀerences p < 0 05 .
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Figure 6: Mean meniscus scoring value concerning the subcategory
“content of proteoglycans”: comparison of the meniscus score
results of cell-free polyurethane scaﬀolds (= cell free) and
mesenchymal stromal cell-loaded scaﬀolds (= MSC) after 6 weeks.
(∗ ) describes signiﬁcant diﬀerences p < 0 05 .
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Figure 7: Mean meniscus scoring value concerning the subcategory
“integration of the scaﬀolds in the surrounding meniscus tissue”:
comparison of the meniscus score results of cell-free polyurethane
scaﬀolds (= cell free) and mesenchymal stromal cell-loaded
scaﬀolds (= MSC) after 6 weeks. (∗ ) describes signiﬁcant
diﬀerences p < 0 05 .
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4. Discussion
In this study, it was shown that an accelerated repair of a
combined avascular and vascular meniscus defect can be
achieved by using a mesenchymal stromal cell-loaded porous
polyurethane scaﬀold in a New Zealand white rabbit model.
After six weeks, the stromal cell-loaded approach showed sig-
niﬁcant advantages in proteoglycan content, integration into
the surrounding native meniscus, and overall scoring com-
pared to the cell-free approach.
However, the treatment of injured meniscus, especially of
lesions located in the avascular zone, remains challenging
due to its poor endogenous regenerative capacity. Partial
meniscectomy often remains the only treatment option,
although it is well known that the loss of meniscus tissue pre-
disposes for the onset of osteoarthritic changes in the knee
joint [3, 5, 7, 12, 45]. So tissue engineering oﬀers new treat-
ment modalities for meniscus repair or even for meniscus
replacement [46].
An accelerated meniscus repair enables patients’ earlier
mobilization and load bearing, thus leading to shorter reha-
bilitation periods. Moﬀet et al. emphasized the importance
of early rehabilitation after meniscus treatment to achieve a
good functional outcome [47]. Furthermore, Eriksson and
Häggmark observed the rapid atrophy of the quadriceps
femoris muscle, after immobilization of the knee joint caused
by surgical procedures [48]. Its rebuilding can be problematic
especially for older patients [49, 50]. However, regaining full
quadriceps strength before returning to extensive stress
exposure is important both in athletes and for the normal
population [51]. Therefore, studies generally recommend
shortened immobilization periods [52, 53]. Importantly, an
accelerated meniscus repair would also mean a drastically
lightened burden for patients with an earlier return to full
weight bearing, to sport activities, and to work.
The mesenchymal stromal cells seem to make a major
contribution to the accelerated regeneration. Due to their
properties to diﬀerentiate to ﬁbrochondrocytes, act on the
vessel growths, and secrete diﬀerent growth factors [54], they
are suitable for cell-based tissue engineering approaches.
Many studies already showed their feasibility for meniscus
regeneration [28, 40, 55]. The application of MSCs alone
and in combination with growth factors and scaﬀolds has
been tested in several in vivo and in vitro studies. In the last
decades, stem cell-based therapies have been translated into
clinical settings [56–58]. For example, Zellner et al. achieved
the repair of meniscal tears in rabbits with the combination
of a hyaluronic acid gelatin scaﬀold and mesenchymal stem
cells [24].
Yu et al. summarized that bone marrow-derived mesen-
chymal stem cells are the most commonly used cell source
in tissue engineering [27].
However, also further cell sources, such as synoviocytes,
meniscus cells, or adipose tissue-derived cells, havebeen tested
concerning their relevance for meniscus regeneration [12]. At
least, the therapeutic capacity of synoviocytes has been
described to be inferior to the capacity of bone marrow-
derived MSCs [59, 60]. Concerning the use of meniscus-
derived MSCs as well as adipose tissue-derived MSCs, a
regeneration-promoting eﬀect in vivo has been reported
[61–63]. However, harvesting and cell isolation as well as the
application protocols of these cells are not as well validated
as for bone marrow-derived MSCs, which advocates the use
of bonemarrow-derivedMSCs.Nevertheless, up to now, there
is no consensus concerning the best cell source for meniscus
regenerative cell-based tissue engineering approaches.
The polyurethane scaﬀold (Actiﬁt, Orteq, London, UK)
used in this study previously showed good results and statisti-
cally signiﬁcant improvements in clinical outcome as well as
improved macroscopic and histological meniscus healing in
both clinical trials [31, 32] as well as in vivo experiments
[64]. Additionally, our own previous studies showed the suit-
ability and advantages of this polyurethane scaﬀold for a cell-
based tissue engineering approach in comparison to another
hyaluronic acid gelatin scaﬀold [44]. Therefore, it was also
considered to be suitable for the implementation of this study.
While the present study showed a signiﬁcant beneﬁt
for the cell-based approach after 6 weeks regarding proteo-
glycan production and integration, the results after 12
weeks did not diﬀer signiﬁcantly between the mesenchy-
mal stromal cell-loaded and cell-free approaches. It has
been shown that the progenitor cell concentration in the
a c b
Figure 8: Left: microscopic view on transversal cut meniscus sections; CD 31 immunohistochemistry staining for the evaluation of vessel
ingrowth. Vascular endothelial cells are stained black. The polyurethane scaﬀold (a) is completely surrounded by native meniscus tissue
(b). Vascular endothelial cells are stained black and are shown by the vessels cuts (c), which were found in the peripheral as well as central
parts of the scaﬀolds; benchmark for the left picture: bar = 500μm. Right: microscopica view, CD 31 immunohistochemistry staining for
the evaluation of vessel ingrowth. Vascular endothelial cells are stained black. (a) demonstrates the polyurethane scaﬀold, and (b) presents
examples of vessel cuts; benchmark for the right picture: bar = 200 μm. Both pictures refer to MSC-loaded scaﬀold group after 6 weeks.
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synovial ﬂuid is elevated after a meniscal injury. This is
presumably due to progenitor cell release from meniscal
tissue [65, 66]. The existence of these cells and their inte-
gration into the polyurethane scaﬀold is a possible expla-
nation for the increase of proteoglycans and type II
collagen content in the group of cell-free scaﬀold after
12 weeks. Furthermore, the increased proteoglycan pro-
duction and integration of the cell-free scaﬀold into the
surrounding native meniscus could be explained by the
cell ingrowth due to neovascularization.
However, in a similar meniscus defect model, Angele
et al. were able to show that only a ﬁbrous muted healing
response can be observed both in untreated menisci and in
menisci treated with an empty hyaluronic acid-based scaﬀold
[67]. Verdonk et al. published a case series with 52 partial
meniscectomies that were treated with a cell-free polyure-
thane scaﬀold [1]. In the two-year follow-up, they demon-
strated a signiﬁcantly improved clinical outcome with a
reduced pain level, better function, and healthier cartilage
state. Other clinical studies also conﬁrmed the safety and
improved clinical outcome using a cell-free polyurethane
scaﬀold for the treatment of both lateral and medial meniscus
defects [31, 32, 68]. Although cell-free scaﬀolds are currently
used in clinics with promising results [34, 69], our results
suggest that this approach could possibly be further
enhanced by the addition of autologous mesenchymal stem
cells [13]. Especially in an early phase of regeneration, load-
ing with mesenchymal stromal cells showed signiﬁcant
advantages in comparison to the cell-free scaﬀold, as shown
in the results after 6 weeks.
In line with our ﬁndings, several studies have shown sta-
tistically signiﬁcant beneﬁts that resulted in loading a scaﬀold
with mesenchymal stem cells compared to cell-free scaﬀolds
[25, 70]. Most likely, this beneﬁt originates from the diﬀeren-
tiation capacity, the ability of paracrine secretion of bioactive
substances, and immunoregulatory properties of mesenchy-
mal stem cells [40, 71, 72].
In the present study, we found extensive vascularization
in the repair tissue both in the cell-free and in the mesenchy-
mal stromal cell-based study groups. These ﬁndings are in
line with results from a previous study, where we showed that
preconditioning of meniscus cells/mesenchymal stem cell-
based tissue engineering products inﬂuences the angiogenic
potential of tissue engineering products [3]. A dense abun-
dance of vessels was present throughout the repair tissue,
remarkably even in parts that correspond to the nonvascular-
ized part of the native meniscus. Apparently, the polyure-
thane scaﬀold seems to promote the ingrowth of vessels.
These results correlate to the results of a clinical study by
Verdonk et al. [39], which also suggested vessel ingrowth into
the repair tissue after three months. However, it is yet to be
determined if this neovascularization has a positive or nega-
tive eﬀect on the meniscus repair. On the one hand, Petersen
et al. [73] found that the vascular endothelial growth factor
(VEGF) coating of a meniscus suture has a negative eﬀect
on meniscus healing. Ahsraf et al. [74] described a positive
correlation between osteoarthritic changes in the knee and
meniscus neovascularization; hence, they proposed that neo-
vascularization and nerve ingrowth might be a reason for
pain genesis in osteoarthritic knees. On the other hand, sev-
eral clinical studies with the same polyurethane scaﬀold that
was used in the present study rather described a signiﬁcant
reduction in pain levels [1, 31, 32, 68]. Furthermore, nee-
dling, rasping, or trephination to promote vessel ingrowth
into damaged meniscus by puncturing healthy tissue is fre-
quently and successfully used in meniscus surgery [75, 76].
It is also generally accepted that the vascular part of the
meniscus has a far greater healing capacity than the avascular
part [7, 24].
Nevertheless, there are a few limitations standing in con-
trast to the strength of the present study. Although we con-
ﬁrmed the isolation of the stromal cell population by plastic
adherence, there was no determination of stem cell markers
or an assessment concerning the multilineage potential of
the harvested MSCs. A further limitation can be seen in the
limited transferability to human meniscus, as the small size
and low weight of New Zealand rabbits lead to diﬀerent sur-
gery circumstances and acting forces in the knee compared to
human knees. Furthermore, the biomechanics of the scaﬀold
have not been assessed in the present study, as biomechanics
and biocompatibility are essential properties of any biomate-
rial. However, this animal model has been established and
extensively tested in our study group before. So several other
authors have considered it to be a suitable model for menis-
cus defects [77–79]. Additionally, bone marrow-derived
MSCs were used, as they are an easily accessible cell source
both preclinical and clinical. Also, the tested polyurethane
scaﬀold has found its way into the everyday clinical applica-
tion. Thus, this setting is well suited to represent the actual
clinical situation.
In further studies, scaﬀolds loaded with diﬀerent speci-
ﬁed cells have to be investigated concerning the best cell
source for tissue engineering-related meniscus regeneration.
As biomechanics are essential properties of any biomaterial
and have not been assessed within this study, they have to
be examined in further studies. Additionally, longer-term
studies are required since no complete meniscus healing
was achieved within the current study period of 12 weeks.
5. Conclusion
The present study showed for the ﬁrst time the accelerated
healing process of tissue engineering products for meniscus
regeneration due to a MSC-based approach. Previous studies
indicated the relevance of vascularization in context to
meniscus regeneration. Vascularization was also documented
in the investigated polyurethane scaﬀolds, which conﬁrms
previous ﬁndings concerning a vascularization-promoting
eﬀect of MSCs in combination with polymer scaﬀolds.
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